Latigo Biotherapeutics (NASDAQ:LTGO) Stock Rating Raised to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Latigo Biotherapeutics (NASDAQ:LTGO – Free Report) from a sell rating to a hold rating in a research report report published on Saturday,Wall Street Zen reports.

LTGO has been the subject of a number of other research reports. Jefferies Financial Group assumed coverage on Latigo Biotherapeutics in a research report on Tuesday, September 1st. They set a “buy” rating and a $50.00 price objective for the company. Weiss Ratings started coverage on Latigo Biotherapeutics in a research report on Tuesday. They issued a “sell (e-)” rating on the stock. Guggenheim started coverage on Latigo Biotherapeutics in a research report on Tuesday, September 1st. They issued a “buy” rating and a $50.00 target price on the stock. The Goldman Sachs Group began coverage on Latigo Biotherapeutics in a research note on Tuesday, September 1st. They set a “buy” rating and a $73.00 price target for the company. Finally, Leerink Partners started coverage on shares of Latigo Biotherapeutics in a research report on Tuesday, September 1st. They set an “outperform” rating and a $36.00 price target for the company. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $52.25.

Read Our Latest Research Report on Latigo Biotherapeutics

Latigo Biotherapeutics Stock Performance

Shares of LTGO opened at $12.60 on Friday. The stock has a market cap of $835.38 million and a price-to-earnings ratio of -0.24. The company’s fifty day moving average is $17.95. Latigo Biotherapeutics has a 1-year low of $10.24 and a 1-year high of $25.93.

Latigo Biotherapeutics (NASDAQ:LTGO – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.55) earnings per share (EPS) for the quarter.

Insider Activity at Latigo Biotherapeutics

In other Latigo Biotherapeutics news, major shareholder Foresite Capital Management V, purchased 140,000 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the purchase, the insider directly owned 2,008,024 shares of the company’s stock, valued at $36,144,432. The trade was a 7.49% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James Tananbaum purchased 140,000 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $2,520,000.00. Following the purchase, the director directly owned 2,008,024 shares in the company, valued at approximately $36,144,432. The trade was a 7.49% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

Key Latigo Biotherapeutics News

Here are the key news stories impacting Latigo Biotherapeutics this week:

  • Positive Sentiment: Latigo reported a third-quarter loss of $0.55 per share, beating analyst estimates by $0.12. Earnings estimate beat
  • Positive Sentiment: The company says Phase 3 bunionectomy and open-label safety trials for onzotrigine remain on track to begin, with topline results expected in the second half of 2027. Third-quarter results and business highlights
  • Positive Sentiment: Latigo appointed pain-sector executive Todd Smith as president and CEO. His commercialization experience could support the company’s plans to advance and potentially commercialize non-opioid pain treatments. CEO appointment
  • Neutral Sentiment: LTGO trading was temporarily paused twice under limit-up/limit-down volatility rules. The pauses indicate heightened volatility, not a specific direction or cause.
  • Negative Sentiment: Despite beating estimates, Latigo still reported a quarterly loss, and the expected Phase 3 readout is not until the second half of 2027, leaving substantial time and clinical-development risk before a potential catalyst. Third-quarter and nine-month results

Latigo Biotherapeutics Company Profile

(Get Free Report)

Latigo Biotherapeutics, Inc is a clinical-stage biopharmaceutical company developing non-opioid treatments for pain. The company focuses on therapies designed to selectively target Nav1.8, a sodium channel expressed in peripheral sensory neurons that plays an important role in the transmission of pain signals.

Latigo’s lead product candidate, LTG-001, is an oral, selective Nav1.8 inhibitor being developed for the treatment of acute and chronic pain conditions. By targeting pain signaling outside the central nervous system, the company aims to develop alternatives to opioid medicines and other pain treatments that may carry significant safety or tolerability concerns.

Recommended Stories

Analyst Recommendations for Latigo Biotherapeutics (NASDAQ:LTGO)

Receive News & Ratings for Latigo Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Latigo Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.